drugset / Trial / NCT06624943
Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali
Phase 4
Completed
260 enrolled
Life for a Child Program, Diabetes Australia
Centre Hospitalier du Luxembourg · collabHospital of Mali · collabSante Diabete Mali · collabUniversity Hospital, Geneva · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting biosimilar insulin glargine delivered by reusable pens combined with short-acting insulin via needle and syringe.
Timeline
- Start
- 2022-03-14
- Primary completion
- 2023-05-05
- Completion
- 2023-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin glargine | Protein / enzyme biologic | — | — |